Liquid biopsy technologies, particularly circulating tumor DNA, or ctDNA, are changing how clinicians monitor hematologic ...

- Nine abstracts across Takeda’s hematology portfolio and pipeline demonstrate Takeda’s commitment to patient-centric, innovative care that aims to drive greater treatment outcomes - Includes data ...

Another disease-related barrier relates to the cytopenias experienced by many patients with HMs because of their disease or its treatment. Treatment of anemia and thrombocytopenia consists mainly of ...

Jennifer Vidrine, MBBS, MRCP, of Newcastle upon Tyne Hospitals, stresses the importance of providing personalized, beneficial end-of-life care for patients with hematologic diseases. Jennifer Vidrine, ...

Ana Lacerda, MD, MSc, of the Portuguese Institute of Oncology, advocates for early palliative care integration in pediatric patients with hematologic diseases. Improving end-of-life care for pediatric ...

Financial Conflicts of Interest: Payment at the Expense of Patients? In the article that accompanies this editorial, Weisse et al 11 present new findings about residential hospice care for patients ...

Advanced systemic mastocytosis (advSM) is a rare and serious form of systemic mastocytosis, a blood disorder that involves the overproduction of mast cells. Mast cells are a type of white blood cell ...

What if we could repair fundamental parts of our bodies? Gene therapy promises just that. It's like having a molecular mechanic that can fix or replace faulty genes, potentially curing diseases ...

TAMPA, FL, UNITED STATES, January 15, 2025 /EINPresswire.com/ -- San Rocco Therapeutics announces the GLOBAL HEMATOLOGICAL RARE DISEASES ALLIANCE hosts a 2-day ...

In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA ...